The development of neutralizing antibodies against SARS-CoV-2 and their common features

• 作者: Liu Daisy Liu Chaoyang Lian Leng-Siew Yeap Fei-Long Meng
• 来源期刊: 分子细胞生物学报（英文版）
• 年，卷（期）: 2020,（12）
• 所属期刊栏目: Reviews
• 页码范围: 980-986
• 页数: 7页
• 语种: 英文
• DOI: 10.1093/jmcb/mjaa070

摘要

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused a worldwide severe coronavirus disease 2019(COVID-19)pandemic since December 2019.There is a great demand for effective therapies for the prevention and treatment of COVID-19.Developing therapeutic neutralizing antibodies(NAbs),which could block viral infection,is such a promising approach,as NAbs have been successfully applied to the treatment of other viral infections.The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs,and many of which are now actively tested in clinical trials.Here,we re-view the approaches applied for SARS-CoV-2 NAb development,and discuss the emerging technologies underlining the antibody discovery.We further summarize the common features of these antibodies including the shared neutralizing epitopes and se-quence features.